<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109418</url>
  </required_header>
  <id_info>
    <org_study_id>F160224001</org_study_id>
    <nct_id>NCT03109418</nct_id>
  </id_info>
  <brief_title>Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea</brief_title>
  <official_title>Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea: A Prospective, Randomized, Controlled, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to substantially reduce overall postoperative morbidity and
      mortality associated with obstructive sleep apnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA) affects millions of people in the U.S., and currently, there is
      not a well-established, general anesthetic technique that clearly decreases the risk of
      postoperative respiratory complications in these patients. If OSA patients have significantly
      decreased postoperative opioid requirements and improved recovery profiles in the PACU, the
      protocol could have significant implications in defining future standardized general
      anesthesia recommendations for patients with this disease. Ultimately, the aim of this study
      is to substantially reduce overall postoperative morbidity and mortality associated with
      obstructive sleep apnea. The objective of this study is to compare the postoperative recovery
      profile of OSA patients receiving standard Sevoflurane inhaled anesthesia with normal saline
      infusion versus Sevoflurane combined with a low-dose ketamine infusion.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment challenges
  </why_stopped>
  <start_date type="Actual">June 2, 2016</start_date>
  <completion_date type="Actual">September 12, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>up to 24 hours postoperatively</time_frame>
    <description>Visual Analog Scale pain rating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Score</measure>
    <time_frame>At 24 hrs post-op</time_frame>
    <description>Patients will rate their quality of anesthesia services</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>OSA patients will receive standard inhaled anesthesia with normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight</description>
    <arm_group_label>Ketamine Group</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>OSA patients receiving standard inhaled anesthesia combined with normal saline</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 19-100

          -  scheduled to undergo general ENT or Orthopedic Surgery

          -  diagnosis of obstructive sleep apnea as confirmed by sleep study or deemed high risked
             for obstructive sleep apnea by clinical predictors (greater than 4 clinical predictors
             of obstructive sleep apnea as described by STOP BANG ).

        Exclusion Criteria:

          -  positive pregnancy test

          -  ASA &gt; III

          -  history of alcohol or narcotic abuse in last 90 days

          -  significant cardiovascular or respiratory disease (baseline oxygen saturation below
             92%)

          -  significant psychiatric or neurologic disease

          -  history of significant hepatic or renal disease (baseline creatinine&gt;1.5)

          -  history of allergy or contraindication to anesthetic agents or ketamine including
             patients with increased ICP

          -  increased IOP

          -  severe arrhythmias

          -  history of delirium

          -  history of hallucinations

          -  history of psychosis

          -  history of uncontrolled seizures

          -  potential risk for malignant hyperthermia (family history)

          -  history of difficult intubation that would preclude standard induction of anesthesia

          -  prisoners

          -  persons who are mentally impaired

          -  non-English speakers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Nagi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Department of Anesthesiology and Perioperative Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <results_first_submitted>October 1, 2019</results_first_submitted>
  <results_first_submitted_qc>December 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2019</results_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Peter A. Nagi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Postoperative morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03109418/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three participants were excluded prior to randomization due to the following reasons:
The patient was experiencing on-going neurological issues and was therefore removed from the study prior to randomization.
The patient missed his/her own surgery date.
The patient ended up having outpatient surgery, and was therefore excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>OSA patients will receive standard inhaled anesthesia with normal saline infusion
Control: OSA patients receiving standard inhaled anesthesia combined with normal saline</description>
        </group>
        <group group_id="P2">
          <title>Ketamine Group</title>
          <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>OSA patients will receive standard inhaled anesthesia with normal saline infusion
Control: OSA patients receiving standard inhaled anesthesia combined with normal saline</description>
        </group>
        <group group_id="B2">
          <title>Ketamine Group</title>
          <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores</title>
        <description>Visual Analog Scale pain rating</description>
        <time_frame>up to 24 hours postoperatively</time_frame>
        <population>Study was terminated. Data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>OSA patients will receive standard inhaled anesthesia with normal saline infusion
Control: OSA patients receiving standard inhaled anesthesia combined with normal saline</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Group</title>
            <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores</title>
          <description>Visual Analog Scale pain rating</description>
          <population>Study was terminated. Data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Score</title>
        <description>Patients will rate their quality of anesthesia services</description>
        <time_frame>At 24 hrs post-op</time_frame>
        <population>Participants were not analyzed due to study being terminated. Data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>OSA patients will receive standard inhaled anesthesia with normal saline infusion
Control: OSA patients receiving standard inhaled anesthesia combined with normal saline</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Group</title>
            <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Score</title>
          <description>Patients will rate their quality of anesthesia services</description>
          <population>Participants were not analyzed due to study being terminated. Data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>OSA patients will receive standard inhaled anesthesia with normal saline infusion
Control: OSA patients receiving standard inhaled anesthesia combined with normal saline</description>
        </group>
        <group group_id="E2">
          <title>Ketamine Group</title>
          <description>OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Sturdivant</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-4042</phone>
      <email>Adamsturdivant@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

